The potential of BTKi therapies in delaying MS progression

touchEXPERT FOCUS for touchNEUROLOGY

Join Prof. Montalban as he shares expert insights into the pathophysiology of progressive MS and the rationale for targeting BTK inhibitors. He reviews emerging clinical data supporting the use of BTK inhibitors and discusses how they may fit into the evolving treatment landscape. In this context, Prof. Montalban also considers current guideline-recommended therapies for progressive MS and highlights key areas of remaining unmet treatment need.

The expert

Prof. Xavier Montalban, Centre d'Esclerosi Múltiple de Catalunya (Cemcat) and Vall d'Hebron University Hospital, Barcelona, Spain

This touchPODCAST is for HCPs outside of the UK only.

This activity is provided by an independent medical education grant from Sanofi. 

The activity is jointly provided by USF Health and touchIME. 

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchneurology.com/